Insulin promotes proliferation, survival, and invasion in endometrial carcinoma by activating the MEK/ERK pathway

Cancer Letters

Volumn 322, Issue 2, 2012, Pages 223-231

  Wang, Yingmei ^a   Zhu, Yuanxi ^a   Zhang, Lizhi ^b   Tian, Wenyan ^a   Hua, Shaofang ^c   Zhao, Jing ^a   Zhang, Huiying ^a   Xue, Fengxia ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN FIRST CENTRAL HOSPITAL   (China)

^c SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Endometrial carcinoma; Insulin; Invasion; MEK ERK pathway; Proliferation

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CYCLIN D1; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN P52; PROTEIN SHC;

ADVANCED CANCER; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GRADING; CANCER TISSUE; CELL INVASION; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; COMPLEX FORMATION; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ENZYME ACTIVATION; FEMALE; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN BLOOD LEVEL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENDOMETRIAL NEOPLASMS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASM INVASIVENESS;

EID: 84861654804     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.03.026     Document Type: Article

References (43)

1. Kitchener H.C., Trimble E.L. Endometrial cancer state of the science meeting. Int. J. Gynecol. Cancer 2009, 19:134-140.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA: Cancer J. Clin. 2012, 62:10-29.
3. Sorosky J.I. Endometrial cancer. Obstet. Gynecol. 2008, 111:436-447.
4. Hjartaker A., Langseth H., Weiderpass E. Obesity and diabetes epidemics: cancer repercussions. Adv. Exp. Med. Biol. 2008, 630:72-93.
5. Wild S., Pierpoint T., Jacobs H., McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31year follow-up study. Hum. Fertil. (Cambridge, England) 2000, 3:101-105.
6. Burghen G.A., Givens J.R., Kitabchi A.E. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J. Clin. Endocrinol. Metab. 1980, 50:113-116.
7. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
8. Gunter M.J., Hoover D.R., Yu H., Wassertheil-Smoller S., Manson J.E., Li J., Harris T.G., Rohan T.E., Xue X., Ho G.Y., Einstein M.H., Kaplan R.C., Burk R.D., Wylie-Rosett J., Pollak M.N., Anderson G., Howard B.V., Strickler H.D. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol. Biomar. Prev. 2008, 17:921-929.
9. Shoff S.M., Newcomb P.A. Diabetes, body size, and risk of endometrial cancer. Am. J. Epidemiol. 1998, 148:234-240.
10. White M.F. Insulin signaling in health and disease. Science (New York, NY) 2003, 302:1710-1711.
11. O'Brien R.M., Streeper R.S., Ayala J.E., Stadelmaier B.T., Hornbuckle L.A. Insulin-regulated gene expression. Biochem. Soc. Trans. 2001, 29:552-558.
12. Mawson A., Lai A., Carroll J.S., Sergio C.M., Mitchell C.J., Sarcevic B. Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1. Mol. Cell. Endocrinol. 2005, 229:161-173.
13. Zhao J., Xue F.X., Hua S.F., Zhang L.Z. Effects of insulin on proliferation and apoptosis of endometrial carcinoma cell. Zhonghua Fu Chan Ke Zazhi 2007, 42:696-700.
14. Kanzaki M., Pessin J.E. Signal integration and the specificity of insulin action. Cell Biochem. Biophys. 2001, 35:191-209.
15. Kharitonenkov A., Chen Z., Sures I., Wang H., Schilling J., Ullrich A. A family of proteins that inhibit signalling through tyrosine kinase receptors. Nature 1997, 386:181-186.
16. Pruett W., Yuan Y., Rose E., Batzer A.G., Harada N., Skolnik E.Y. Association between GRB2/Sos and insulin receptor substrate 1 is not sufficient for activation of extracellular signal-regulated kinases by interleukin-4: implications for Ras activation by insulin. Mol. Cell. Biol. 1995, 15:1778-1785.
17. Lavoie J.N., L'Allemain G., Brunet A., Muller R., Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J. Biol. Chem. 1996, 271:20608-20616.
18. Cubas R., Zhang S., Li M., Chen C., Yao Q. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol. Cancer 2010, 9:253.
19. Weber J.D., Raben D.M., Phillips P.J., Baldassare J.J. Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase. Biochem. J. 1997, 326(Pt 1):61-68.
20. Ravenhall C., Guida E., Harris T., Koutsoubos V., Stewart A. The importance of ERK activity in the regulation of cyclin D1 levels and DNA synthesis in human cultured airway smooth muscle. Br. J. Pharmacol. 2000, 131:17-28.
21. Xu J., Keeton A.B., Franklin J.L., Li X., Venable D.Y., Frank S.J., Messina J.L. Insulin enhances growth hormone induction of the MEK/ERK signaling pathway. J. Biol. Chem. 2006, 281:982-992.
22. Kang S., Song J., Kang H., Kim S., Lee Y., Park D. Insulin can block apoptosis by decreasing oxidative stress via phosphatidylinositol 3-kinase- and extracellular signal-regulated protein kinase-dependent signaling pathways in HepG2 cells. Eur. J. Endocrinol./Eur. Fed. Endocr. Soc. 2003, 148:147-155.
23. Golding S.E., Rosenberg E., Valerie N., Hussaini I., Frigerio M., Cockcroft X.F., Chong W.Y., Hummersone M., Rigoreau L., Menear K.A., O'Connor M.J., Povirk L.F., van Meter T., Valerie K. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol. Cancer Ther. 2009, 8:2894-2902.
24. Lathi R.B., Hess A.P., Tulac S., Nayak N.R., Conti M., Giudice L.C. Dose-dependent insulin regulation of insulin-like growth factor binding protein-1 in human endometrial stromal cells is mediated by distinct signaling pathways. J. Clin. Endocrinol. Metab. 2005, 90:1599-1606.
25. Kayali A.G., Austin D.A., Webster N.J. Stimulation of MAPK cascades by insulin and osmotic shock: lack of an involvement of p38 mitogen-activated protein kinase in glucose transport in 3T3-L1 adipocytes. Diabetes 2000, 49:1783-1793.
26. Godsland I.F. Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin. Sci. (Lond.) 2009, 118:315-332.
27. Lunghi P., Tabilio A., Pinelli S., Valmadre G., Ridolo E., Albertini R., Carlo-Stella C., Dall'Aglio P.P., Pelicci P.G., Bonati A. Expression and activation of SHC/MAP kinase pathway in primary acute myeloid leukemia blasts. Hematol. J. 2001, 2:70-80.
28. Finlayson C.A., Chappell J., Leitner J.W., Goalstone M.L., Garrity M., Nawaz S., Ciaraldi T.P., Draznin B. Enhanced insulin signaling via Shc in human breast cancer. Metab. Clin. Exp. 2003, 52:1606-1611.
29. Davol P.A., Bagdasaryan R., Elfenbein G.J., Maizel A.L., Frackelton A.R. Shc proteins are strong, independent prognostic markers for both node-negative and node-positive primary breast cancer. Cancer Res. 2003, 63:6772-6783.
30. Daly R.J., Binder M.D., Sutherland R.L. Overexpression of the Grb2 gene in human breast cancer cell lines. Oncogene 1994, 9:2723-2727.
31. Yu G.Z., Chen Y., Wang J.J. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J. Cancer Res. Clin. Oncol. 2009, 135:1331-1339.
32. Sivaraman V.S., Wang H., Nuovo G.J., Malbon C.C. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Investig. 1997, 99:1478-1483.
33. Mizumoto Y., Kyo S., Mori N., Sakaguchi J., Ohno S., Maida Y., Hashimoto M., Takakura M., Inoue M. Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis. Cancer Sci. 2007, 98:652-658.
34. Ruhul Quddus M., Latkovich P., Castellani W.J., James Sung C., Steinhoff M.M., Briggs R.C., Miranda R.N. Expression of cyclin D1 in normal, metaplastic, hyperplastic endometrium and endometrioid carcinoma suggests a role in endometrial carcinogenesis. Arch. Pathol. Lab. Med. 2002, 126:459-463.
35. Choudhury M., Bansal S. Expression of cyclin D1 in endometrial hyperplasia and endometrial carcinoma. Indian J. Pathol. Microbiol. 2007, 50:708-710.
36. Li Z., Wang C., Prendergast G.C., Pestell R.G. Cyclin D1 functions in cell migration. Cell Cycle (Georgetown, Tex) 2006, 5:2440-2442.
37. Call R., Grimsley M., Cadwallader L., Cialone L., Hill M., Hreish V., King S.T., Riche D.M. Insulin-carcinogen or mitogen? Preclinical and clinical evidence from prostate, breast, pancreatic, and colorectal cancer research. Postgrad. Med. 2010, 122:158-165.
38. White P.B., True E.M., Ziegler K.M., Wang S.S., Swartz-Basile D.A., Pitt H.A., Zyromski N.J. Insulin, leptin, and tumoral adipocytes promote murine pancreatic cancer growth. J. Gastrointest. Surg. 2010, 14:1888-1893.
39. (discussion 1893-1894).
40. Lai A., Sarcevic B., Prall O.W., Sutherland R.L. Insulin/insulin-like growth factor-I and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell Cycle progression in MCF-7 breast cancer cells through differential regulation of cyclin E and p21(WAF1/Cip1). J. Biol. Chem. 2001, 276:25823-25833.
41. Chappell J., Leitner J.W., Solomon S., Golovchenko I., Goalstone M.L., Draznin B. Effect of insulin on cell cycle progression in MCF-7 breast cancer cells. Direct and potentiating influence. J. Biol. Chem. 2001, 276:38023-38028.
42. Qi H.L., Zhang Y., Ma J., Guo P., Zhang X.Y., Chen H.L. Insulin/protein kinase B signalling pathway upregulates metastasis-related phenotypes and molecules in H7721 human hepatocarcinoma cell line. Eur. J. Biochem./FEBS 2003, 270:3795-3805.
43. Montagut C., Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 2009, 283:125-134.